Interpace Diagnostics Group (IDXG) AI Stock Analysis

• Market Cap: $7.90M
• Dividend Yield: N/A
• Average Volume (3M): 11.58K
• Price to Earnings (P/E): 1.1
• Beta (1Y): 1.25
• Revenue Growth: -6.64%
• EPS Growth: -29.74%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.03
• Shares Outstanding: 4,428,539
• 10 Day Avg. Volume: 15,402
• 30 Day Avg. Volume: 11,583
• PEG Ratio: <0.01
• Price to Book (P/B): -5.34
• Price to Sales (P/S): 0.25
• P/FCF Ratio: 3.14
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 0.17
• Enterprise Value/Gross Profit: 0.27
• Enterprise Value/Ebitda: 1.19
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: $1.50 ▲(59.57% Upside)
• Action: Upgraded Date: 01/20/26
• Date: Action: Upgraded 01/20/26

The score is primarily supported by improving profitability and cash generation, reinforced by positive corporate actions (debt repayment and capital structure simplification). Technicals also show a steady uptrend. The main offset is balance sheet risk from negative equity, despite recent cleanup progress, while valuation appears attractive based on a low P/E.

Positive Factors

Improved cash generation

Sustained recovery in operating and free cash flow reduces dependence on external financing and supports reinvestment in lab automation, sales, and R&D. Strong cash conversion gives management flexibility to fund growth initiatives and withstand industry cyclicality over the next several quarters.

High and expanding margins

Robust gross and operating margins indicate durable unit economics in the thyroid testing franchise, enabling scalable profitability as volumes rise. Higher margins support investment capacity and improve resilience against pricing or reimbursement pressures common in diagnostics.

Simplified capital structure and deleveraging

Early loan repayment and conversion of preferred shares into common reduce interest burden and complexity, improving financial flexibility. A cleaner balance sheet enhances ability to invest commercially and pursue an uplisting, broadening capital access and supporting medium‑term growth plans.

Negative Factors

Negative shareholders' equity

Persisting negative equity signals historical losses or prior financing that can limit access to capital and strategic options. Even with debt reduction, negative equity can constrain covenants, lender confidence, and limit ability to absorb shocks or fund larger strategic investments over the coming months.

Concentration of revenue in one franchise

A full pivot to thyroid testing increases operational and market risk from single‑product concentration. Adverse reimbursement, competitive entrants, or regulatory changes in thyroid diagnostics could materially impact revenue and growth durability without diversified product lines.

High insider/private equity ownership concentration

Two firms controlling a large majority of shares can expedite strategic moves but may limit minority shareholder influence and prioritize sponsor objectives. This concentration raises governance and liquidity risks and could lead to future dilution or strategic decisions misaligned with public investors.

Interpace Diagnostics Group Business Overview & Revenue Model

Company Description

Interpace Diagnostics Group (IDXG) is a biotechnology company specializing in developing and commercializing molecular diagnostic tests for cancer and other diseases. The company operates primarily in the healthcare sector, focusing on providing innovative diagnostic solutions that aid in the early detection and management of cancer, particularly in the gastrointestinal field. IDXG's core products include a portfolio of molecular tests designed to improve diagnostic accuracy and inform treatment decisions for patients, thereby enhancing patient outcomes.

How the Company Makes Money

IDXG generates revenue primarily through the sale of its diagnostic tests, which are utilized by healthcare providers to assess and diagnose cancer. The company's revenue model includes direct sales to hospitals and laboratories, as well as partnerships with other healthcare organizations and pharmaceutical companies that may utilize IDXG's technologies in their services. Additionally, IDXG may earn revenue through reimbursement from insurance providers for the diagnostic tests performed, which is a significant revenue stream. The company also engages in collaborations and licensing agreements that can enhance its market presence and generate additional income, contributing to its overall earnings.

Interpace Diagnostics Group Financial Statement Overview

Summary

Income statement strength (75) shows improving profitability and solid revenue growth, and cash flow (70) reflects stronger operating and free cash generation. However, the balance sheet score (45) is weighed down by negative equity, which remains a key financial risk despite progress in reducing debt.

Income Statement

Interpace Diagnostics Group has shown a significant improvement in its income statement metrics over the recent years. The gross profit margin for 2024 stands at 63.8%, reflecting efficient cost management. The net profit margin improved to 14.3%, indicating strong profitability. Revenue growth rate from 2023 to 2024 was 16.7%, showing solid growth momentum. The EBIT margin of 17.3% and EBITDA margin of 17.8% for 2024 suggest robust operating performance. Overall, the income statement reveals a positive growth trajectory and improved profitability.

Balance Sheet

The balance sheet shows ongoing financial challenges, with a negative stockholders' equity of -$2.2 million in 2024, indicating potential solvency issues. However, the company has reduced its debt levels significantly over time, with a debt-to-equity ratio improvement as total debt decreased to $1.18 million. Return on equity is not meaningful due to negative equity. The equity ratio remains negative, further emphasizing balance sheet weaknesses. Improvements in reducing debt and liabilities are positive steps, but negative equity poses risks.

Cash Flow

Cash flow analysis highlights a strong recovery in cash generation capabilities. The operating cash flow in 2024 was $4.65 million, significantly higher than in previous years. Free cash flow improved to $3.77 million, indicating better cash management. The free cash flow growth rate from 2023 to 2024 is 13.6%, showcasing effective capital allocation. The operating cash flow to net income ratio of 0.69 indicates efficient cash conversion. Overall, the cash flow statement reflects positive trends in liquidity and cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Mar 2021
Income Statement
Total Revenue	41.82M	46.93M	40.21M	31.84M	41.31M	32.40M
Gross Profit	27.00M	29.93M	23.90M	18.23M	17.95M	10.72M
EBITDA	6.06M	8.36M	3.84M	-2.27M	-1.33M	-20.10M
Net Income	4.81M	6.70M	802.00K	-5.87M	-14.75M	-26.20M
Balance Sheet
Total Assets	12.04M	14.79M	13.02M	15.98M	38.43M	45.68M
Cash, Cash Equivalents and Short-Term Investments	1.42M	1.46M	3.50M	4.83M	3.31M	2.77M
Total Debt	864.00K	5.86M	11.19M	16.09M	13.72M	4.74M
Total Liabilities	12.33M	17.01M	28.16M	79.05M	80.84M	74.76M
Stockholders Equity	-298.00K	-2.22M	-15.14M	-63.07M	-42.42M	-29.08M
Cash Flow
Free Cash Flow	4.43M	3.77M	3.32M	-8.01M	-9.07M	-16.15M
Operating Cash Flow	4.88M	4.65M	3.79M	-7.69M	-8.72M	-14.58M
Investing Cash Flow	-447.00K	-876.00K	-87.00K	6.21M	-315.00K	-1.57M
Financing Cash Flow	-5.12M	-5.81M	-5.03M	3.00M	8.98M	16.61M

Interpace Diagnostics Group Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.94
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXG, the sentiment is Neutral. The current price of 0.94 is below the 20-day moving average (MA) of 1.80, below the 50-day MA of 1.55, and below the 200-day MA of 1.07, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 53.81 is Neutral, neither overbought nor oversold. The STOCH value of 54.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IDXG.

Interpace Diagnostics Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDXG	71 Outperform	$7.90M	1.09	―	―	-6.64%	-29.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYNZ	48 Neutral	$7.58M	-0.13	―	―	―	―
BIAF	45 Neutral	$4.28M	-0.16	-245.18%	―	-27.66%	13.18%
INBS	44 Neutral	$6.58M	-0.85	-146.12%	―	3.26%	65.96%
NDRA	42 Neutral	$4.49M	-0.64	-236.34%	―	―	98.86%

Interpace Diagnostics Group Corporate Events

Interpace Diagnostics Guides 2026 Growth After Balance Sheet Cleanup

Interpace Biosciences reported preliminary, unaudited 2025 revenue from continuing operations of approximately $38–39 million, of which $34–35 million came from thyroid testing, reflecting 21% growth in thyroid testing revenue over 2024 following the discontinuation of its PancraGEN test in May 2025 and a full pivot to its thyroid diagnostics franchise. The company issued initial 2026 revenue guidance of about $40 million, all from thyroid testing, and further simplified its balance sheet by confirming that, after an October 2024 exchange of Series B into Series C preferred shares, all Series C preferred stock has now been converted into roughly 23.3 million common shares, leaving about 27.7 million basic shares outstanding, a debt-free balance sheet, and a fully common equity capital structure; with majority ownership held by private equity investors 1315 Capital and Ampersand, Interpace plans to leverage its improved financial position and profitability to seek an uplisting to the Nasdaq Stock Market in 2026, a move that could broaden its investor base and support additional investment in sales, R&D, and lab automation.

The most recent analyst rating on (IDXG) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Interpace Diagnostics Group stock, see the IDXG Stock Forecast page.

Interpace Biosciences Repays Loan Early for Growth

On December 3, 2025, Interpace Biosciences announced the early repayment of its term loan facility with BroadOak Capital Partners, ahead of its maturity date. This move eliminates interest expenses and enhances operational flexibility, allowing the company to focus on commercial growth and strengthen its balance sheet, as it continues to deliver record testing volumes and revenue for its thyroid tests.

The most recent analyst rating on (IDXG) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Interpace Diagnostics Group stock, see the IDXG Stock Forecast page.